Yakira urges Atrium Therapeutics to launch strategic review

• Yakira Capital Management on Oct. 20, 2026 urged Atrium Therapeutics to launch a strategic review, including a potential sale.
• The shareholder called for tighter spending controls and transparent estimates of capital needed to reach key clinical milestones.
• Yakira questioned the Oct. 8 financing, which raised $50 million at an effective price of approximately $7.93 per share.
• It estimated pre-financing third-quarter net cash at approximately $254 million, or $14.85 per share, arguing the stock traded substantially below cash value.
• The board had not responded to Yakira's Oct. 9 letter urging strategic alternatives, prompting the shareholder to take its concerns public.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY75892) on October 20, 2026, and is solely responsible for the information contained therein.